Fellowship · Portland, OR
Sponsored by Oregon Health & Science University (OHSU Health)
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Molecular cancer · 2023 · 1,738 citations · Nathalie Javidi-Sharifi
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
The New England journal of medicine · 2021 · 2,264 citations · Tomasz Beer
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet (London, England) · 2024 · 686 citations · Matthew Taylor
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 213 citations · Elie Traer
Ponsegromab for the Treatment of Cancer Cachexia.
The New England journal of medicine · 2024 · 260 citations · Eric Roeland
Preoperative Treatment of Locally Advanced Rectal Cancer.
The New England journal of medicine · 2023 · 399 citations · Hagen Kennecke
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.
The New England journal of medicine · 2025 · 127 citations · Jared Acoba
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
The New England journal of medicine · 2022 · 422 citations · Eva Medvedova